Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydroxyurea + azathioprine + alemtuzumab + thiotepa + plerixafor + total body irradiation + cyclophosphamide + sirolimus
- Development stage
- Preclinical
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous, Subcutaneous, Intrathecal, External Radiation
01
Overview
This is a combination conditioning regimen used in hematopoietic cell transplantation. It includes multiple chemotherapeutic agents (hydroxyurea, azathioprine, thiotepa, cyclophosphamide), an immunosuppressant (sirolimus), a monoclonal antibody (alemtuzumab), a stem cell mobilizer (plerixafor), and radiation therapy (total body irradiation). This intensive combination is likely used for preparing patients with hematologic malignancies or other conditions for stem cell transplantation by depleting bone marrow cells and suppressing the immune system to prevent graft rejection.
02
Targets
RNR (Ribonucleotide reductase)CXCR4 (C-X-C motif chemokine receptor 4)CD52 (CD52 Antigen)Mechanistic target of rapamycin complex 1DNARAC1 (Rac family small GTPase 1)
Beyond the preview
Go deeper on hydroxyurea + azathioprine + alemtuzumab + thiotepa + plerixafor + total body irradiation + cyclophosphamide + sirolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydroxyurea + azathioprine + alemtuzumab + thiotepa + plerixafor + total body irradiation + cyclophosphamide + sirolimus.